"We found out the using IRIS intraoperatively during partial nephrectomy does help us with preserving renal parenchyma," says Teona Iarajuli.
In this video, Teona Iarajuli discusses the background and findings from her study, “Does utilizing IRIS, a segmented three-dimensional model, preserve renal parenchymal volume during robotic partial nephrectomy?”, which was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Iarajuli is a fourth year medical student at Hackensack Meridian School of Medicine in New Jersey.
Video Transcript:
Could you describe the background for this study?
IRIS is a 3D anatomical model that is interactive, and it's actually made out of CT scans. It gives you an ability to rotate and directly pull the tumor out of the kidney during the surgery. It gives you a much better visual field during partial nephrectomy. So, our goal in our study was to find out does IRIS actually help us to preserve renal parenchyma in high nephrometry score complicated cases during partial nephrectomy.
What were some of the notable findings?
We found out the using IRIS intraoperatively during partial nephrectomy does help us with preserving renal parenchyma via making the surgery more precise, compared to non-IRIS patients. I just want to emphasize that using this 3D model of IRIS does have a potential to improve patient outcomes post-partial nephrectomy, especially by preserving more renal parenchyma and also just making the surgery much more precise than without IRIS.
This transcription has been edited for clarity.
Grant awarded to aid development of allogeneic CAR T treatment for RCC
April 29th 2024“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.